Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Shionogi Set to Make “QOL Diseases” Next Leg of Business: CEO
Shionogi is looking to grow what it dubs “QOL diseases” as the next pillar of its business alongside the infectious diseases sector, with the CEO voicing his high hopes for Quviviq (daridorexant), an insomnia drug recently licensed from Nxera Pharma.…
To read the full story
Related Article
- Shionogi Eyes Faster QOL Biz Expansion with Ex-JT Researchers: CEO
February 2, 2026
- Shionogi to Buy Torii in 160 Billion Yen Deal, JT Pulls Plug on Pharma Biz
May 8, 2025
- Insomnia Med Quviviq Now Available in Japan: Nxera/Shionogi
December 20, 2024
- Shionogi Sole Distributor of Nxera’s Insomnia Med in Japan
October 2, 2024
BUSINESS
- Halaven Generics Obtain Soft Tissue Sarcoma Use
September 3, 2026
- Ono Teams with Aitia in AI-Driven Neurology Drug Discovery
September 3, 2026
- Nippon Kayaku’s Generic Sunitinib Gains Pancreatic NET Use
September 3, 2026
- GSK Hit with MHLW Guidance over Sponsored Lecture
September 2, 2026
- Nonprescription Cialis Goes Nationwide in Japan, Now at 10,000 Outlets
September 2, 2026
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
More than a year after Dupixent (dupilumab) became the first antibody therapy approved for COPD in Japan, drug makers are…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…